Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €63.71 EUR
Change Today +0.118 / 0.19%
Volume 0.0
JUD On Other Exchanges
Symbol
Exchange
Berlin
As of 2:16 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (JUD) Snapshot

Open
€63.49
Previous Close
€63.59
Day High
€63.71
Day Low
€63.49
52 Week High
04/23/15 - €70.13
52 Week Low
10/15/14 - €44.00
Market Cap
17.8B
Average Volume 10 Days
70.9
EPS TTM
--
Shares Outstanding
280.1M
EX-Date
03/27/15
P/E TM
--
Dividend
€1.19
Dividend Yield
1.41%
Current Stock Chart for ST JUDE MEDICAL INC (JUD)

st jude medical inc (JUD) Related Businessweek News

View More BusinessWeek News

st jude medical inc (JUD) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (JUD) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (JUD) Key Developments

St. Jude Medical, Inc. Receives FDA Approval for the Upgradeable MR-Conditional Spinal Cord Stimulation System

St. Jude Medical Inc. announced FDA approval of the company’s Protégé MRI spinal cord stimulation system. In addition to the approval of the new Protégé MRI system, St. Jude Medical has also secured FDA approval for MRI compatibility of the company’s 60cm Octrode percutaneous leads, which has received MR-conditional labeling for use with the Protégé MRI system. The Protégé MRI system is the smaller MR-conditional SCS implantable pulse generator (IPG) available in the United States, and the only upgradeable IPG on the market to allow patients to safely undergo head and extremity MRI scans. Upgradeable technology allows patients to access future SCS technology from St. Jude Medical, once approved, through software updates rather than surgical device replacement. Historically, most patients would need additional surgery to receive new product features and benefits.

St. Jude Medical Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended April 4, 2015; Provides Earnings Guidance for the Second Quarter and Full Year of 2015

St. Jude Medical Inc. announced unaudited consolidated earnings results for the first quarter ended April 4, 2015. For the quarter, the company reported net sales of $1,345 million compared to $1,363 million a year ago. Operating profit was $325 million compared to $312 million a year ago. Earnings before non-controlling interest and income taxes were $308 million compared to $292 million a year ago. Net earnings attributable to the company were $262 million or $0.91 per diluted share compared to $249 million or $0.86 per diluted share a year ago. Adjusted diluted net earnings per share attributable to the company were $0.93 compared to $1.01 a year ago. Adjusted earnings before non-controlling interest and income taxes were $316 million compared to $349 million a year ago. Net earnings attributable to the company were $266 million or $0.93 per diluted share compared to $291 million or $1.01 per diluted share a year ago. For the second quarter of 2015, the company expects diluted net earnings per share attributable to the company in the range from $0.86 to $0.88 a year ago. The company estimated amortization of intangible assets of $0.06, R&D credit of $0.02 and adjusted diluted net earnings per share attributable to the company in the range from $0.99 to $1.01. The company expects total sales of $1,448 million and sales in the range from $1,370 million to $1,395 million. The company expects revenue to grow in the range of 4% to 5% on a constant currency basis compared to the second quarter of 2014 with currency negatively impacting second quarter revenue by approximately $125 million to $135 million. For the full year of 2015, the company expects diluted net earnings per share attributable to the company in the range from $3.54 to $3.59 a year ago. The company estimated amortization of intangible assets of $0.22, R&D credit of $0.07 and adjusted diluted net earnings per share attributable to the company in the range from $3.92 to $3.97. The company expects total sales of $5,622 million and sales in the range from $5,440 million to $5,515 million. The company expects total revenue to grow in the range of 4% to 5% on a constant currency basis with currency negatively impacting full-year 2015 revenue by approximately $385 million to $410 million. The company expects effective tax rate to be in the range of 17.5% to 18.0%.

St. Jude Medical Inc. to Report Q1, 2015 Results on Apr 22, 2015

St. Jude Medical Inc. announced that they will report Q1, 2015 results at 6:15 AM, Central Daylight on Apr 22, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €63.71 EUR +0.118

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.37 USD -0.51
Olympus Corp ¥4,320 JPY -20.00
Smith & Nephew PLC 1,112 GBp -2.00
Terumo Corp ¥3,045 JPY -45.00
Zimmer Holdings Inc $110.51 USD -0.17
View Industry Companies
 

Industry Analysis

JUD

Industry Average

Valuation JUD Industry Range
Price/Earnings 20.7x
Price/Sales 3.7x
Price/Book 5.4x
Price/Cash Flow 18.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.